Not medical advice: Educational content only. Author is not a doctor. Consult a licensed healthcare professional.
Educational summary of scientific literature on fenbendazole in oncology research
Critical Disclaimer: Fenbendazole is NOT approved for cancer treatment. This content is educational only. Fenbendazole has documented liver toxicity in humans. Always consult a licensed oncologist.
Fenbendazole is a benzimidazole compound originally developed as an antiparasitic agent for veterinary use. It has drawn research interest due to laboratory findings related to microtubule disruption and cellular metabolism.
The compound belongs to the same family as mebendazole and albendazole, which are approved for human use as antiparasitic medications.
Preclinical studies suggest it may affect cellular structures and processes involved in division through mechanisms including:
These findings raise research questions only. Fenbendazole has documented liver toxicity in humans. Any consideration must be discussed with a licensed oncologist due to safety and regulatory concerns.
Human use of veterinary products can be dangerous. There are reports of people experiencing serious liver injury after taking veterinary fenbendazole without medical supervision. Any use of repurposed drugs should be discussed with a qualified healthcare professional.
Case reports document elevated liver enzymes (ALT, AST) and potential liver injury. Regular liver function monitoring is essential if considering any off-label use under medical supervision.